- Conditions
- Patent Foramen Ovale, Cardiac Implantable Electronic Device
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1681–1704
of 7,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
- Conditions
- Liver Resection, Colorectal Carcinoma Liver Metastases
- Interventions
- HRX215 capsules, Placebo capsules
- Drug
- Lead sponsor
- HepaRegeniX GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Rochester, Minnesota • Durham, North Carolina + 1 more
- Conditions
- Food Allergy
- Interventions
- Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg, Viaskin Placebo
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • San Diego, California • Stanford, California + 9 more
- Conditions
- Atopic Dermatitis
- Interventions
- BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo
- Drug
- Lead sponsor
- Brexogen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Driving Impaired
- Interventions
- Cyclobenzaprine 10 Mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Neurana Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Long Beach, California • Atlanta, Georgia
- Conditions
- Peripheral Nerve Injury, Crush Injury
- Interventions
- 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
- Conditions
- Heart Failure
- Interventions
- vicadrostat, empagliflozin, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
- Conditions
- Major Depressive Disorder
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Glendale, California • Oceanside, California + 12 more
- Conditions
- Covid19, Multisystem Inflammatory Syndrome in Children
- Interventions
- Larazotide Acetate, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Respiratory Health
- Interventions
- Teramune Botanical Extract, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Nutraceuticals Research Institute
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Franklin, Tennessee
- Conditions
- Depression
- Interventions
- Risperidone and placebo comparator
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Healthy Subjects
- Interventions
- Acetylsalicyclic acid (Fast release Aspirin, BAY1019036), Acetaminophen (Tylenol extra strength), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 16 Years to 45 Years
- Enrollment
- 510 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Keloid
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- ST-246, Placebo
- Drug
- Lead sponsor
- SIGA Technologies
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Rabies
- Interventions
- CL184, HRIG, Placebo matching CL184
- Biological
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Major Depressive Disorder, Depression
- Interventions
- Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
- Drug · Device
- Lead sponsor
- Marta Peciña, MD PhD
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Dyslipidemia
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Lincoln, California • Palm Springs, California + 11 more
- Conditions
- Chronic Pruritus of Unknown Origin
- Interventions
- Remibrutinib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Fremont, California • Tampa, Florida • Sandy Springs, Georgia + 6 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 58
- States / cities
- Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more
- Conditions
- Plaque Psoriasis
- Interventions
- (CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more
- Conditions
- Opioid Dependence, Acute Opioid Withdrawal Syndrome
- Interventions
- Lofexidine HCl, Placebo, Open Label Lofexidine HCL
- Drug
- Lead sponsor
- USWM, LLC (dba US WorldMeds)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 18
- States / cities
- Clovis, California • Escondido, California • San Diego, California + 15 more
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Interventions
- Dalbavancin, Dalbavancin-matching Placebo
- Drug
- Lead sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 25
- States / cities
- Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more